Sharp Therapeutics Corp.
SHRX.V
TSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.98M | 817.50K | 617.80K | 782.40K | 446.80K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.51M | 3.91M | 3.54M | 3.25M | 2.54M |
| Operating Income | -5.51M | -3.91M | -3.54M | -3.25M | -2.54M |
| Income Before Tax | -6.17M | -3.33M | -2.92M | -5.29M | -3.26M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -6.17 | -3.33 | -2.92 | -5.29 | -3.26 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.17M | -3.33M | -2.92M | -5.29M | -3.26M |
| EBIT | -5.51M | -3.91M | -3.54M | -3.25M | -2.54M |
| EBITDA | -5.50M | -3.90M | -3.52M | -3.23M | -2.48M |
| EPS Basic | -0.22 | -0.12 | -4.96 | -17.94 | -26.66 |
| Normalized Basic EPS | -0.14 | -0.08 | -3.11 | -9.61 | -13.59 |
| EPS Diluted | -0.22 | -0.12 | -4.96 | -17.94 | -26.66 |
| Normalized Diluted EPS | -0.14 | -0.08 | -3.11 | -9.61 | -13.59 |
| Average Basic Shares Outstanding | 115.66M | 123.44M | 93.60M | 64.07M | 35.99M |
| Average Diluted Shares Outstanding | 115.66M | 123.44M | 93.60M | 64.07M | 35.99M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |